AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 35606137
Drug: RED-D (Re-Engineered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RED-D (Re-Engineered Discharge for Depression) - a 12-week post-discharge telehealth intervention including cognitive behavioral therapy, self-management support, and patient navigation.
Trial: 35606137
Drug: RED-only (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RED-only (standard Re-Engineered Discharge without depression treatment)
Trial: 33749913
Drug: EPA and
RxNorm normalized name: Norwegian Cod Liver Oil With EPA and DHA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EPA and DHA, 3.36 g daily
Trial: 35026396
Drug: Inhaled nebulized
RxNorm normalized name: Hydra-Neb Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled nebulized 30 mg sodium nitrite twice a day for 12 weeks
Trial: 33986493
Drug: 0 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 mg caffeine (11 g of decaffeinated coffee)
Trial: 33986493
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg caffeine (5.5 g of caffeinated plus 5.5 g of decaffeinated coffee)
Trial: 33986493
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg caffeine (11 g of caffeinated coffee)
Trial: 36045392
Drug: Practice change
RxNorm normalized name: monofluorophosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Practice change intervention including Brief advice to abstain from alcohol and information about potential risks; referral to phone coaching service for medium-risk and Drug and Alcohol Service for high-risk women.
Trial: 34466793
Drug: Emotional Freedom
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Emotional Freedom Techniques (EFT) applied for 16 weeks in the immediate treatment group (ITG)
Trial: 33393364
Drug: Individual Cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individual Cognitive Stimulation Therapy (iCST), 40 sessions over 20 weeks
Trial: 32538123
Drug: Targeted Behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Targeted Behavioral Therapy (TBT)
Trial: 33352724
Drug: HFCS-SB (high
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HFCS-SB (high fructose corn syrup)
Trial: 35534349
Drug: Synergy drug
RxNorm normalized name: Senergy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Synergy drug eluting stent (DES)
Trial: 35534349
Drug: Xience drug
RxNorm normalized name: Ruxience
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Xience drug eluting stent (DES)
Trial: 33320406
Drug: Topical minoxidil
RxNorm normalized name: MINOXIDIL 50 mg in 1 mL TOPICAL SOLUTION [Stafenit Hair Regrowth Treatment Topical Minoxidil]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical minoxidil gel 5%
Trial: 33320406
Drug: Topical spironolactone
RxNorm normalized name: spironolactone Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical spironolactone gel 1%
Trial: 33320406
Drug: Combined minoxidil
RxNorm normalized name: Minoxidil
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Combined minoxidil 5% and spironolactone 1% gel
Trial: 35597332
Drug: Protocol-based potassium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protocol-based potassium supplementation (oral potassium chloride to maintain serum potassium of 4-5 mEq/L)
Trial: 35597332
Drug: Conventional potassium
RxNorm normalized name: Potassium
DrugBank: Potassium (DB14500)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional potassium supplementation (reactive supplementation when serum potassium is <3.5 mEq/L)
Trial: 32817595
Drug: Cortex Phellodendri
RxNorm normalized name: adrenal cortex extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cortex Phellodendri Compound Fluid (CPCF)
Trial: 32817595
Drug: Kangfuxin solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kangfuxin solution (KFS)
Trial: 32250171
Drug: One standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One standard serving (∼11‐15 g) daily of a preferred alcoholic beverage
Trial: 33070469
Drug: Propofol (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (10 mg/mL)
Trial: 34794685
Drug: β-blocker withdrawal
RxNorm normalized name: capsaicin
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: β-blocker withdrawal (arm A: n = 26)
Trial: 34794685
Drug: Continuing β-blocker
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuing β-blocker treatment (arm B: n = 26)
Trial: 37103592
Drug: Physical exercise
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical exercise and dietary therapy (PED-t)
Trial: 33798751
Drug: Intracoronal bleaching
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracoronal bleaching treatment with 35 % hydrogen peroxide for 40 min (Control group)
Trial: 33798751
Drug: Intracoronal bleaching
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracoronal bleaching treatment assisted with Er,Cr:YSGG laser (2780 nm) operating at 1.25 W for 30 s
Trial: 33798751
Drug: Intracoronal bleaching
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracoronal bleaching treatment assisted with Er,Cr:YSGG laser (2780 nm) operating at 2.5 W for 30 s
Trial: 33126096
Drug: Training healthcare
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Training healthcare workers as change agents in a Social and Behavioural Change Communication workshop, supported by a social marketing campaign.
Trial: 32941094
Drug: Control without
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control without surface treatment (Groups 1 & 5)
Trial: 33000478
Drug: Additional 10
RxNorm normalized name: chromous chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Additional 10 minutes of 1-on-1 instruction by a trained physical therapy student or dental faculty member
Trial: 35452688
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion amiodarone
Trial: 36459908
Drug: Topical olive
RxNorm normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical olive oil dressing plus standard care (wound irrigation with normal saline and oral antibiotics) for four weeks
Trial: 33793110
Drug: Acupuncture plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture plus medication (tamsulosin hydrochloride 0.2 mg nightly)
Trial: 33793110
Drug: Medication (tamsulosin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication (tamsulosin hydrochloride 0.2 mg nightly)
Trial: 34739450
Drug: Dexmedetomidine (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (0.5 μg/kg/hour)
Trial: 34739450
Drug: Propofol (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (2 mg/kg/hour)
Trial: 33252241
Drug: Equine-Assisted Activity
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Equine-Assisted Activity (EAA) program, 40 minutes twice a week for 16 weeks (32 sessions)
Trial: 34564020
Drug: Nintedanib (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nintedanib (150 mg twice daily)
Trial: 33740344
Drug: Transforaminal (TF)
RxNorm normalized name: transforming growth factor beta 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transforaminal (TF) cervical epidural steroid injection
Trial: 33740344
Drug: Parasagittal interlaminar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parasagittal interlaminar (IL) cervical epidural steroid injection
Trial: 36226676
Drug: 60-min massage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60-min massage doses
Trial: 36226676
Drug: 30-min massage
RxNorm normalized name: histamine
DrugBank: Histamine (DB05381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 30-min massage doses
Trial: 36226676
Drug: 15-min massage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15-min massage doses
Trial: 36226676
Drug: 3×/week massage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3×/week massage doses
Trial: 36226676
Drug: 15-min doses
RxNorm normalized name: diazepam
DrugBank: Diazepam (DB00829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 15-min doses
Trial: 34491142
Drug: Frenotomy for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Frenotomy for PTT (surgical treatment arm, n = 24)
Trial: 34928182
Drug: Intravenous lipid
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous lipid emulsion (ILE)
Trial: 33657762
Drug: Neurogenic acupoint
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neurogenic acupoint dry cupping therapy plus lifestyle modifications for 8 weeks
Trial: 35620204
Drug: AI technology
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: AI technology combined with ultrasound-guided needle knife interventional therapy
Trial: 36215289
Drug: Gefitinib plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gefitinib plus pemetrexed-based chemotherapy
Trial: 33108484
Drug: Low-concentration peptide-HAP
RxNorm normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Low-concentration peptide-HAP suspension (0.5 wt% HAP; Curodont, Credentis)
Trial: 33108484
Drug: High-concentration peptide-HAP
RxNorm normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High-concentration peptide-HAP suspension (6.25% HAP; Curodont Protect)
Trial: 33108484
Drug: Commercial bleaching
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Commercial bleaching agent (VivaStyle Paint on Plus, VS, Ivoclar Vivadent)
Trial: 32753571
Drug: Barbed suturing
RxNorm normalized name: oxytetracycline hydrochloride Oral Tablet [5-Way Calf Scour Bolus]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Barbed suturing of the joint capsule (group B)
Trial: 32289474
Drug: 15 day
RxNorm normalized name: Tudorza Pressair 15 Day 400mcg/actuation Powder for Inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 day hypofractionated PMRT regimen (3.33 Gy daily to the chest wall and regional lymphatics in 11 fractions, with optional 4 fraction mastectomy scar boost)
Trial: 35502503
Drug: High-volume TFEB
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-volume TFEB with steroids (group D)
Trial: 35502503
Drug: High-volume TFEB
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-volume TFEB without steroids (group L)
Trial: 32306987
Drug: Maintenance targeted
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance targeted therapy after chemotherapy
Trial: 32306987
Drug: Agents with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Agents with a positive efficacy signal
Trial: 35307550
Drug: 3 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg/kg CBD
Trial: 35609202
Drug: Family planning
RxNorm normalized name: Lubricant Topical application Gel/Jelly [FAMILY PLANNING LIQUID LUBRICANT]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Family planning intervention (FP) including up to six counseling sessions, free transportation to FP clinic, free FP services, and treatment for contraceptive-related side effects.
Trial: 35122952
Drug: Individual and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individual and group supportive therapy
Trial: 33924645
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D (150,000 IU) administered 24 hours before the run
Trial: 33191598
Drug: Exposure to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exposure to antidepressant conspiracy theories (Study 3)
Trial: 35466013
Drug: Systemic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic therapy optimisation
Trial: 32479786
Drug: Intravenous haloperidol
RxNorm normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous haloperidol dose escalation at 2 mg every 4 h
Trial: 32479786
Drug: Neuroleptic rotation
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neuroleptic rotation with chlorpromazine at 25 mg every 4 h
Trial: 32479786
Drug: Combined haloperidol
RxNorm normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Combined haloperidol at 1 mg and chlorpromazine at 12·5 mg every 4 h
Trial: 33037990
Drug: Once-weekly carfilzomib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-weekly carfilzomib plus dexamethasone (Kd) 20/70 mg/m2
Trial: 33037990
Drug: Twice-weekly carfilzomib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice-weekly carfilzomib plus dexamethasone (Kd) 20/27 mg/m2
Trial: 35133671
Drug: Losartan 100
RxNorm normalized name: LOSARTAN 100MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan 100 mg orally once daily for 24 weeks
Trial: 32629112
Drug: Oral (PO)
RxNorm normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral (PO) antibiotic therapy
Trial: 32629112
Drug: Intravenous (IV)
RxNorm normalized name: intravenous (IV) infusion pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) antibiotic therapy
Trial: 32629112
Drug: Duration of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duration of antibiotic therapy
Trial: 33421042
Drug: Clam Extract
RxNorm normalized name: clam allergenic extract
DrugBank: Quahog, unspecified (DB11009)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clam Extract (CE) capsules, 3 times a day for 2 weeks
Trial: 33421042
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group received empty capsules identical in appearance to CE capsules
Trial: 34293124
Drug: DHA (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHA (4 g/day for 4 weeks in the form of DHA-rich fish oil)
Trial: 34293124
Drug: ALA (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALA (4 g/day for 4 weeks in the form of ALA-rich flaxseed oil)
Trial: 32096243
Drug: Delayed FGG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed FGG group (8 implants from control group)
Trial: 35045327
Drug: Ertugliflozin (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ertugliflozin (5 mg once daily orally administered)
Trial: 34137538
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of Carbimazole (OD-CMZ)
Trial: 34137538
Drug: Divided dose
RxNorm normalized name: Aluminum Zirconium Trichlorohydrex Gly 20 g in 100 g TOPICAL STICK [Dividends]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Divided dose of Carbimazole (DD-CMZ)
Trial: 32076558
Drug: Newer generation
RxNorm normalized name: regenerated cellulose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Newer generation drug-eluting stents (simple stenting)
Trial: 32076558
Drug: Newer generation
RxNorm normalized name: regenerated cellulose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Newer generation drug-eluting stents (complex stenting)
Trial: 36226089
Drug: Extracorporeal shockwave
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Extracorporeal shockwave therapy (ESWT) combined with conventional treatment
Trial: 33218350
Drug: Letrozole plus
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Letrozole plus human menopausal gonadotropin (HMG) for endometrial preparation
Trial: 33218350
Drug: Routine artificial
RxNorm normalized name: COLOR,ARTIFICIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine artificial hormonal endometrial preparation
Trial: 32801017
Drug: Oral THC:CBD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral THC:CBD cannabis extract (2.5 mg THC and 2.5 mg CBD, 1-4 self-titrated capsules, three times daily from days -1 to 5)
Trial: 32801017
Drug: Oral THC:CBD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral THC:CBD cannabis extract
Trial: 33219115
Drug: Eccentric exercise
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eccentric exercise therapy (EET)
Trial: 32805185
Drug: Voglibose 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Voglibose 0.2 mg 3 times daily
Trial: 34500113
Drug: Concurrent treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent treatment (SBRT with immunotherapy)
Trial: 34500113
Drug: Sequential treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential treatment (SBRT followed by immunotherapy)
Trial: 32329037
Drug: Statin administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin administration (statin + group, 143 patients)
Trial: 32329037
Drug: No statin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No statin administration (statin - group, 201 patients)
Trial: 32329037
Drug: Statin administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin administration (statin + group)
Trial: 32329037
Drug: No statin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No statin administration (statin - group)
Trial: 32034447
Drug: 7-mg nicotine
RxNorm normalized name: nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 7-mg nicotine patch (NP)
Trial: 32034447
Drug: Placebo patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo patch (PP)
Trial: 36541117
Drug: Chemotherapy (C)
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (C)
Trial: 34454767
Drug: 2-scale combination
RxNorm normalized name: wing scale pollen extract
DrugBank: Atriplex canescens pollen (DB10767)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-scale combination (0,1/2,3 or 0/1,2)
Trial: 34773608
Drug: Inhaled Technosphere
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled Technosphere Insulin (TI) at doses of 10, 30, and 120 U
Trial: 34773608
Drug: Subcutaneous insulin
RxNorm normalized name: subcutaneous insulin pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous insulin lispro (LIS) at doses of 8, 30, and 90 U
Trial: 35471812
Drug: Clarithromycin 500
RxNorm normalized name: clarithromycin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin 500 mg, amoxicillin 1000 mg, esomeprazole 40 mg, all twice daily for 14 days
Trial: 35471812
Drug: Bismuth subcitrate
RxNorm normalized name: BISMUTH SUBCITRATE
DrugBank: Bismuth subcitrate potassium (DB09275)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bismuth subcitrate 240 mg twice daily, amoxicillin 1000 mg three times daily, esomeprazole 40 mg twice daily for 14 days
Trial: 34155568
Drug: Brivaracetam 100
RxNorm normalized name: brivaracetam 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brivaracetam 100 mg/day
Trial: 35007940
Drug: ICDs exposed
RxNorm normalized name: lactose, x-ray exposed (1000 rad)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICDs exposed to doses of 2, 5, or 10 Gy (6 MV) during radiation exposure
Trial: 35007940
Drug: PMs exposed
RxNorm normalized name: lactose, x-ray exposed (1000 rad)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PMs exposed to doses of 2, 5, or 10 Gy (6 MV) during radiation exposure
Trial: 35708557
Drug: Aromatherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aromatherapy with lavender oil through inhalation and foot massage
Trial: 32216468
Drug: Lactobacillus fermentum
RxNorm normalized name: Lactobacillus Fermentum
DrugBank: Lactobacillus fermentum (DB16542)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus fermentum CECT5716 (Lc40) administered to mothers (n=139); 1 capsule/day containing 3×10^9 cfu Lc40
Trial: 32216468
Drug: Placebo (maltodextrin)
RxNorm normalized name: Maltodextrin
DrugBank: Maltodextrin (DB12583)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (maltodextrin) capsule administered to mothers (n=152); 1 capsule/day
Trial: 38508877
Drug: RAAS blockers
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RAAS blockers
Trial: 32957418
Drug: Electroacupuncture (EA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electroacupuncture (EA) treatment, 12 sessions over 4 weeks
Trial: 32957418
Drug: Manual acupuncture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual acupuncture (MA) treatment, 12 sessions over 4 weeks
Trial: 32957418
Drug: Western medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Western medicine group, 20 mg fluoxetine orally per day for 4 weeks
Trial: 32957418
Drug: Manual acupuncture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual acupuncture (MA) treatment
Trial: 32330638
Drug: 200 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 μg misoprostol
Trial: 33509703
Drug: Standard-of-care basal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-of-care basal insulin (SOC-BI)
Trial: 36215911
Drug: Video observation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Video observation of methadone take-home dosing
Trial: 33634446
Drug: Restarting oral
RxNorm normalized name: levonorgestrel
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Restarting oral anticoagulation within 14 days